No products in the cart.
Cat:GMP-h-PG-I
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Gastric disease (atrophic gastritis,
pernicious anemia, intestinal metaplasia, dysplasia, gastric polyps, and
gastric cancer) and related syndrome. GeneMedi offers paired diagnostics grade pepsinogen I (PG I) antibodies (monoclonal antibody, mab) and antigens for Gastric disease (atrophic gastritis,
pernicious anemia, intestinal metaplasia, dysplasia, gastric polyps, and
gastric cancer) rapid test kit of pepsinogen I (PG I) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Gastric disease (atrophic gastritis,
pernicious anemia, intestinal metaplasia, dysplasia, gastric polyps, and
gastric cancer ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.There are two main types of pepsinogen (PG), namely PG I (PG A) and PG II (PG C). Both of these types are produced in the essential cells in the stomach corpus and fundus and in mucous cervical cells. Unlike PG A, PG C is also produced in the Brunner glands in the proximal duodenum and in the pyloric glands in the antrum [8]. Serum pepsinogen levels reflect the morphological and functional status of the stomach mucosa, so they serve as markers of chronic atrophic gastritis [9]. Low levels of serum PG A and PG A / PG C are observed in patients with atrophic gastritis, pernicious anemia, intestinal metaplasia, dysplasia, gastric polyps, and gastric cancer [8].
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261308/
Product Description
Cat No. of Pruducts
GMP-h-PG-I-Ag01:Recombinant Human PG I Protein
Product Name
Recombinant Human PG I Protein
Target
pepsinogen I
Alias of Target/Biomarker
#N/A
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
pepsinogen I (PG I) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in PG I level test of Gastric disease (atrophic gastritis,
pernicious anemia, intestinal metaplasia, dysplasia, gastric polyps, and
gastric cancer) and related syndrome evaluation
Tag
His
Products description
Recombinant Human PG I Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-PG-I-Ab01,GMP-h-PG-I-Ab02:Anti-Human PG I mouse monoclonal antibody (mAb)
Product Name
Anti-Human PG I mouse monoclonal antibody (mAb)
Target
pepsinogen I? (PG I)
Alias of Target/Biomarker
#N/A
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human pepsinogen I (PG I) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other pepsinogen I (PG I) antibodies in PG I level test of Gastric disease (atrophic gastritis,
pernicious anemia, intestinal metaplasia, dysplasia, gastric polyps, and
gastric cancer) and related syndrome evaluation.
Tag
mFc
Products description
Anti-Human PG I mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other pepsinogen I (PG I) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
